IPO Databook: Shenzhen Immunofoco Biotechnology (HK) - Aug 2026

118 Views20 Aug 2026 10:10

SUMMARY

Shenzhen Immunofoco Biotechnology, founded in 2020, is an innovative cell therapy company developing CAR-T therapies for solid tumors, hematological malignancies, and autoimmune diseases.
The company has one Core Product, IMC002, in a registrational Phase III clinical trial in China, with eight self-developed candidates in its pipeline.
As of June 30, 2026, cash and cash equivalents were 401,854 thousand RMB, and total assets were 550,963 thousand RMB.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream